Tracking babies born to moms on rare disease drug
NCT ID NCT07345494
Summary
This study aims to gather safety information about the drug YORVIPATH during pregnancy and breastfeeding. It will follow about 50 women with hypoparathyroidism who took the drug around the time of pregnancy. Researchers will collect data on pregnancy complications, birth outcomes, and the baby's health for at least the first year of life to understand any potential risks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ascendis Investigational Site
RECRUITINGMorgantown, West Virginia, 26508, United States
Conditions
Explore the condition pages connected to this study.